GlassScriptPhysician profile
Beverly A Armstrong
NPI 1386833341
$2,510.28
in general payments reported to CMS, 2019-2025
11 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609 · 2022: $463 · 2023: $675 · 2024: $279 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $680.69 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $426.23 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $402.95 | 2021-2024 | |
| Indivior INC. | $354.81 | 2021-2025 | Sublocade, Perseris |
| Braeburn INC. | $237.70 | 2023-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $159.42 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $134.38 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $34.79 | 2025 | |
| Janssen Pharmaceuticals, INC | $30.25 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.15 | 2025 | Caplyta |
| Orexo US, INC. | $18.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.